Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
- Conditions
- Chronic ProstatitisChronic Pelvic Pain Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03500159
- Locations
- 🇺🇸
Site 1016, Los Angeles, California, United States
🇺🇸Site 1020, Los Angeles, California, United States
🇺🇸Site 1001, Cleveland, Ohio, United States
Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study
- Conditions
- Healthy Volunteer
- Interventions
- Drug: Combined Oral Contraceptive
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03478020
- Locations
- 🇳🇱
PRA Health Sciences - Early Development Serices, Groningen, Netherlands
Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03185195
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome
- Conditions
- Chronic Interstitial CystitisInterstitial CystitisBladder Pain SyndromePainful Bladder Syndrome
- Interventions
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Target Recruit Count
- 433
- Registration Number
- NCT02858453
- Locations
- 🇨🇦
Site 1016, Sherbrooke, Quebec, Canada
🇺🇸Site 9005, Boston, Massachusetts, United States
🇪🇸Site 1401, Aravaca, Spain
Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2018-10-05
- Lead Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02324972
- Locations
- 🇨🇦
AQX-Innovaderm site, Montreal, Quebec, Canada
Efficacy and Safety of AQX-1125 in Unstable COPD
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT01954628
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
ðŸ‡ðŸ‡ºCsongrád Megyei Melkasi Betegségek Szakkórháza, Deszk, Hungary
🇦🇺Department of Respiratory & Sleep Medicine, Westmead Hospital, Wentworthville, New South Wales, Australia
Efficacy and Safety of AQX-1125 in IC/BPS
- Conditions
- Bladder Pain SyndromeInterstitial Cystitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT01882543
- Locations
- 🇨🇦
AQX/CMX Site, Vancouver, British Columbia, Canada
🇨🇦Dr Lesley Carr, Toronto, Ontario, Canada
🇨🇦AQX/CMX site, Sherbrooke, Quebec, Canada